Dose-intensive therapy for breast cancer.
O'Shaughnessy
J A
JA
Medical Breast Cancer Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Cowan
K H
KH
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology*; D016026:Bone Marrow Transplantation / Q000379:methods; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D018014:Gene Transfer Techniques; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011960:Receptors, Estrogen / Q000032:analysis; D016879:Salvage Therapy; D013629:Tamoxifen / Q000008:administration & dosage
D011960:Receptors, Estrogen; D013629:Tamoxifen; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D002955:Leucovorin; D005472:Fluorouracil